BTK Inhibitors in R/R CLL: Navigating Options and Tailoring Treatment

home / peer-exchange / btk-inhibitors-in-r-r-cll-navigating-options-and-tailoring-treatment

Callie Coombs, MD; Matthew Davids, MD, MMSc; Seema Bhat, MD; and Lori Leslie, MD, discuss venetoclax-obinutuzumab therapy, pirtobrutinib’s progression-free survival data from the BRUIN CLL-321 trial at ASH 2024, Bruton tyrosine kinase (BTK) inhibitor safety profiles, cost considerations under the Inflation Reduction Act, and clinical strategies for managing BTK inhibitor toxicity.

EP. 1: Fixed-Duration Options for CLL

Callie Coombs, MD ;Matthew Davids, MD, MMSc ;Seema Bhat, MD ;Lori Leslie, MD

December 20th 2024

Panelists discuss how fixed-duration options like venetoclax plus obinutuzumab show promise in treating chronic lymphocytic leukemia (CLL) by offering defined treatment periods rather than indefinite therapy.

Watch

EP. 2: Pirtobrutinib in the BRUIN CLL-321 Study

Callie Coombs, MD ;Matthew Davids, MD, MMSc ;Seema Bhat, MD ;Lori Leslie, MD

January 2nd 2025

Panelists discuss how pirtobrutinib demonstrated superior progression-free survival compared with standard Bruton tyrosine kinase (BTK) inhibitors in previously treated chronic lymphocytic leukemia (CLL) patients as shown in the BRUIN CLL-321 trial results.

Watch

EP. 3: Incorporating Emerging BTK Therapies Into the CLL Treatment Landscape

Callie Coombs, MD ;Matthew Davids, MD, MMSc ;Seema Bhat, MD ;Lori Leslie, MD

January 10th 2025

Panelists discuss how emerging data from ASH 2024 and recent NCCN guidelines supporting pirtobrutinib use in later-line CLL treatment are prompting oncologists to carefully evaluate factors like BTK resistance patterns and the potential role of novel BTK degraders when selecting therapy for relapsed/refractory patients.

Watch

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777